MedTrace Logo

Determination of the Prevalence of Unrecognized Heart Failure Among Patients at Risk in Urban Areas Across Germany Using CMR

NCT07185100 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 600

Last updated 2026-04-01

No results posted yet for this study

Summary

Heart failure (HF) in patients at risk is often overlooked, and when detected, there is a lack of early and effective preventive interventions. The WE-CARE-HF-CMR study, conducted in large cities/metropol areas in Germany ( \> 1.000.000 inhabitants), aims to close this gap by evaluating the feasibility of a mobile, telemedicinemonitored HF-screening approach combining cardiac magnetic resonance imaging (CMR), quality of life assessment and laboratory tests as key elements in asymptomatic patients at risk. WE-CARE-HF-CMR will provide a proposal for a comprehensive, contemporary screening approach for patients at risk to develop HF tailored to the needs of the target population. This will provide important new information on the prevalence of asymptomatic HF in at-risk patients in urban versus rural areas.

The results of the study will be compared with the results from the "HERZCheck'' trial, which provides data from approximately 4,500 participants in rural areas in Germany and has already been completed (NCT05122793).

Conditions

  • Heart Failure With Preserved Ejection Fraction (HFPEF)
  • Renal Dysfunction
  • Stage B Heart Failure

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Philips Healthcare

    collaborator INDUSTRY

  • Deutsches Herzzentrum der Charité, Berlin

    collaborator UNKNOWN

  • German Heart Center Foundation

    collaborator UNKNOWN

  • Nationale Herzallianz (NHA)

    collaborator UNKNOWN

  • Deutsche Herzstiftung

    collaborator UNKNOWN

  • German Heart Institute

    lead OTHER

Principal Investigators

  • Sebastian Kelle, Prof. Dr. · Deutsches Herzzentrum der Charité

Eligibility

Min Age
40 Years
Max Age
69 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-13
Primary Completion
2026-12-31
Completion
2036-12-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07185100 on ClinicalTrials.gov